

CITATION REPORT

List of articles citing

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.

DOI: 10.2337/dc21-1113
Diabetes Care, 2022, , .

Source: <https://exaly.com/paper-pdf/125339086/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Serial measurement of B-type natriuretic peptide and future cardiovascular events in patients with type 2 diabetes mellitus without known cardiovascular disease.. <i>International Journal of Cardiology</i> , 2022 ,	3.2	0
22	Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction. <i>Molecular and Cellular Biochemistry</i> ,	4.2	
21	Microstructure: a potential path to elucidate sex-specific pathological mechanisms in heart failure?. <i>Heart</i> , heartjnl-2022-321250	5.1	0
20	Update Typ-2-Diabetes.		
19	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. 2022 , 38, 1153-1167		1
18	Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. 2022 , 21,		0
17	Toward a new model for the management of type 2 diabetes: The mountain is there and there is no other option than to climb it. 2022 , 184, 106443		0
16	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).		12
15	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).		16
14	An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. 13,		0
13	Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.		0
12	Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.		0
11	Type 2 diabetes. 2022 ,		5
10	Heart Failure and Kidney Disease in Type 2 Diabetes. 2022 , 80, 1732-1734		0
9	What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. 2023 , 24, 570		0
8	Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. 2023 , 100056		1
7	Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. e074068		0

- 6 Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis. ○
- 5 Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?. ○
- 4 Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. ○
- 3 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). **2023**, 22, ○
- 2 GLP-1-Rezeptor-Agonisten: Für welche Personen mit Diabetes mellitus Typ 2?. **2023**, 112, 324-328 ○
- 1 Treatment of type 2 diabetes. ○